Finance

Lists
STAR:NSE
Strides Pharma Science Ltd
1 026,90 ₹
+1,92%
(+19,30) 1D
8 қар., 15:29:58 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
1 002,60 ₹
High
1 009,00 ₹
Low
991,80 ₹
Mkt. cap
94,66 млрд
Avg. vol.
347,50 м.
Volume
0,00
Dividend
0,49%
Quarterly dividend
1,25 ₹
Ex-dividend date
2026 ж. 31 шіл.
P/E ratio
15,35
52-wk high
1 260,90 ₹
52-wk low
768,65 ₹
EPS
66,90 ₹
Shares outstanding
89,55 млн
No. of employees
4 мың
Open
1 002,60 ₹
High
1 009,00 ₹
Low
991,80 ₹
Mkt. cap
94,66 млрд
Avg. vol.
347,50 м.
Volume
0,00
Dividend
0,49%
Quarterly dividend
1,25 ₹
Ex-dividend date
2026 ж. 31 шіл.
P/E ratio
15,35
52-wk high
1 260,90 ₹
52-wk low
768,65 ₹
EPS
66,90 ₹
Shares outstanding
89,55 млн
No. of employees
4 мың
News stories
From web sources and news partners
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3,54 мың
Founded1990
HeadquartersБангалор, Карнатака, Үндістан
SectorHealth Care
IndustryPharmaceutical industry
Websitestrides.com
Last report
2026 ж. 30 қаз.
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
14,30 млрд / 14,15 млрд
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
2026 ж. қыр.
Revenue
11,95 млрд
13,23 млрд
12,65 млрд
14,30 млрд
Cost of goods sold
4,63 млрд
7,19 млрд
4,95 млрд
6,29 млрд
Cost of revenue
4,63 млрд
7,19 млрд
4,95 млрд
6,29 млрд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,30 млрд
3,45 млрд
2,43 млрд
2,38 млрд
Operating expense
5,46 млрд
4,91 млрд
5,97 млрд
6,07 млрд
Total operating expenses
10,09 млрд
12,10 млрд
10,92 млрд
12,36 млрд
Operating income
1,85 млрд
1,13 млрд
1,73 млрд
1,94 млрд
Other non operating income
1,07 млрд
-1,66 млрд
48,90 млн
40,83 млн
EBT including unusual items
2,45 млрд
1,48 млрд
2,00 млрд
1,50 млрд
EBT excluding unusual items
2,49 млрд
502,07 млн
1,36 млрд
1,52 млрд
Income tax expense
373,53 млн
187,70 млн
341,23 млн
163,18 млн
Effective tax rate
15,22%
12,68%
17,09%
10,85%
Other operating expenses
2,66 млрд
928,53 млн
2,97 млрд
3,11 млрд
Net income
2,02 млрд
1,27 млрд
1,57 млрд
1,31 млрд
Net profit margin
16,92%
9,59%
12,40%
9,15%
Earnings per share
-
-
-
-
Interest and investment income
-
404,82 млн
-
-
Interest expense
-433,79 млн
-130,82 млн
-405,61 млн
-465,41 млн
Net interest expenses
-433,79 млн
274,00 млн
-405,61 млн
-465,41 млн
Depreciation and amortization charges
506,23 млн
532,49 млн
563,99 млн
572,15 млн
EBITDA
2,25 млрд
1,55 млрд
2,15 млрд
2,51 млрд
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары